Toth Financial Advisory’s Heron Therapeutics HRTX Stock Holding History

Toth Financial Advisory’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-85	Closed	-$1K	–	762
2021 Q2	$1K	Hold	85	–	–	﹤0.01%	649
2021 Q1	$1K	Hold	85	–	–	﹤0.01%	639
2020 Q4	$2K	Hold	85	–	–	﹤0.01%	537
2020 Q3	$1K	Hold	85	–	–	﹤0.01%	524
2020 Q2	$1K	Hold	85	–	–	﹤0.01%	506
2020 Q1	$1K	Buy	+85	New	+$1.6K	﹤0.01%	423

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Toth Financial Advisory's HRTX Position: Q3 2021 in Review

Toth Financial Advisory sold out of Heron Therapeutics (HRTX) in Q3 2021, closing a stake of 85 shares — an estimated $1K sold.

Toth Financial Advisory first reported a position in HRTX in Q1 2020 and held it in 6 quarters. The position peaked at $2K in Q4 2020. 197 funds tracked by Wall St. Rank hold HRTX as of Q3 2021.

Toth Financial Advisory reported no remaining Heron Therapeutics position as of Q3 2021 after selling out during the quarter.
Toth Financial Advisory sold 85 Heron Therapeutics shares in Q3 2021, an estimated $1K.
Toth Financial Advisory first reported a position in Heron Therapeutics in Q1 2020 and held it in 6 quarters.
Toth Financial Advisory's Heron Therapeutics position peaked at $2K in Q4 2020.
197 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2021.

Based on Toth Financial Advisory's 13F filing for Q3 2021, filed 20 Oct 2021.